Market Research Logo

Radiodermatitis - Pipeline Review, H1 2015

Radiodermatitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Radiodermatitis - Pipeline Review, H1 2015’, provides an overview of the Radiodermatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiodermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiodermatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Radiodermatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Radiodermatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Radiodermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Radiodermatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Radiodermatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Radiodermatitis Overview
Therapeutics Development
Pipeline Products for Radiodermatitis - Overview
Pipeline Products for Radiodermatitis - Comparative Analysis
Radiodermatitis - Therapeutics under Development by Companies
Radiodermatitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Radiodermatitis - Products under Development by Companies
Radiodermatitis - Companies Involved in Therapeutics Development
APEIRON Biologics AG
ProCertus BioPharm Inc.
Reata Pharmaceuticals, Inc.
Stemnion, Inc
Vida Therapeutics Inc.
Radiodermatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Amnion Derived Cellular Cytokine Solution - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APN-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PrC-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTA-408 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VTI-1000 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiodermatitis - Recent Pipeline Updates
Radiodermatitis - Dormant Projects
Radiodermatitis - Discontinued Products
Radiodermatitis - Product Development Milestones
Featured News & Press Releases
Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis
Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study
Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis
Mar 05, 2013: Apeiron Biologics's Liposomal Formulation Of Recombinant Superoxide Dismutase Achieves All Endpoints In Clinical Study
Aug 22, 2012: Apeiron Biologics Receives €510,000 ZIT Grant For Further Development Of APN201 Project
Feb 27, 2012: Apeiron Initiates Clinical Study To Investigate Prevention Of Radiation-Induced Skin Damage In Breast Cancer Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Radiodermatitis, H1 2015
Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Radiodermatitis - Pipeline by APEIRON Biologics AG, H1 2015
Radiodermatitis - Pipeline by ProCertus BioPharm Inc., H1 2015
Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H1 2015
Radiodermatitis - Pipeline by Stemnion, Inc, H1 2015
Radiodermatitis - Pipeline by Vida Therapeutics Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Radiodermatitis Therapeutics - Recent Pipeline Updates, H1 2015
Radiodermatitis - Dormant Projects, H1 2015
Radiodermatitis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Radiodermatitis, H1 2015
Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report